ERBB2 and gastric cancer: Although several clinical studies have confirmed that ICIs combined with chemotherapy can improve the prognosis of patients with HER-2-negative metastatic gastric cancer (GC) (23), the benefit is predominantly observed in patients with positive CPS PD-L1 expression.